source; lin
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326
  • The trial will take place in Paris and is designed to assess the compound’s efficacy in reversing aging facial skin
  • 20 participants, aged 40-65 with specific signs of aging, will be involved
  • Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary platform technology
  • Sirona Biochem Corp. was unchanged at $0.14 at 11:43 AM ET

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.

The trial will take place in Paris and is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles.

The formulation is a cream base with TFC-1326 at a concentration of 1.0 per cent and no other active ingredients.

The trial design was done with the assistance of a leading organization in commercial aesthetics.

20 participants, aged 40-65 with specific signs of aging, will be involved.

Participants will begin in weeks 1 through 3 as a rolling start and continue for a 12-week period using the product twice daily. Ten parameters will be measured using advanced technology.

These include skin radiance, skin laxity, antioxidant analysis, anti-inflammation, wrinkles, skin plumping and product tolerance. The clinical trial is fully financed, owned and controlled by Sirona.

“We’ve been conducting R&D on the anti-aging project for many years and have seen amazing efficacy and unique activity in cell studies,” noted Dr. Howard Verrico, CEO.

“To make the transition to human skin will be a major achievement for the company and the science team in France, and the incredible work that has been done so far has shown that these compounds are unlike anything else available on the market today,” he added.

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety.

Sirona Biochem Corp. was unchanged at $0.14 at 11:43 AM ET.


More From The Market Herald
Parkview Project in New World Island, Newfoundland

" Lithium One (TSXV:LONE) expands land position in Northwest Ontario

Lithium One Metals (LONE) has signed an agreement to acquire an additional lithium property.

" Candente Copper (TSX:DNT) Closes Private Placement With Fortescue Metals

Candente Copper (DNT) closes the previously announced private placement with Nascent Exploration Fortescue Metals Group, raising $4,000,000.

" BeWhere (TSXV:BEW) launches BeMini asset tracker on Geotab Marketplace

BeWhere (BEW) announced the launch of its BeMini on Geotab’s Marketplace.

" LithiumBank (TSXV:LBNK) to develop Boardwalk and Park Place lithium brine projects

LithiumBank Resources (LBNK) has released key milestones for its Boardwalk and Park Place lithium projects.